Arcus Biosciences - 51 Year Dividend History | RCUS

Historical dividend payout and yield for Arcus Biosciences (RCUS) since 1971. The current TTM dividend payout for Arcus Biosciences (RCUS) as of May 23, 2022 is $0.00. The current dividend yield for Arcus Biosciences as of May 23, 2022 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.357B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio